Psychotic Disorders - Australia | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$50.70m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.84%, resulting in a market volume of US$52.86m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$115.20 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Australia is experiencing significant growth and development in recent years.

Customer preferences: One of the key customer preferences in the Psychotic Disorders market in Australia is the increasing demand for personalized treatment options. Patients are seeking tailored therapies that address their specific symptoms and needs. This trend is driven by the growing awareness and understanding of different types of psychotic disorders, as well as the recognition that each patient may respond differently to treatment. As a result, pharmaceutical companies are investing in research and development to create innovative therapies that can be customized for individual patients.

Trends in the market: One of the major trends in the Psychotic Disorders market in Australia is the shift towards non-pharmacological interventions. While medication remains a cornerstone of treatment for psychotic disorders, there is a growing recognition of the importance of holistic approaches that encompass psychological and social interventions. This trend is driven by the desire to minimize the side effects associated with long-term medication use and to improve overall patient outcomes. As a result, there is an increasing focus on therapies such as cognitive-behavioral therapy, family therapy, and supported employment programs.Another trend in the market is the increasing use of digital health technologies. Mobile applications, wearable devices, and telemedicine platforms are being utilized to enhance the delivery of care for individuals with psychotic disorders. These technologies enable remote monitoring, real-time feedback, and self-management tools, empowering patients to actively participate in their treatment and recovery. The adoption of digital health solutions is driven by the need for more accessible and convenient care, especially in rural and remote areas of Australia.

Local special circumstances: Australia has a well-established healthcare system that provides universal access to medical services, including mental health care. This accessibility, combined with a high level of awareness and education about mental health, has contributed to the growth of the Psychotic Disorders market in the country. Additionally, the Australian government has implemented various initiatives and programs to support individuals with mental health conditions, including psychotic disorders. These efforts have increased the availability of resources and funding for research, treatment, and support services.

Underlying macroeconomic factors: The growth of the Psychotic Disorders market in Australia is also influenced by underlying macroeconomic factors. Australia has a stable economy with a high level of disposable income, which enables individuals to afford the cost of treatment and medication. Moreover, the country has a strong pharmaceutical industry and a robust regulatory framework that supports innovation and investment in the development of new therapies. These factors create a favorable environment for pharmaceutical companies to enter and expand in the Psychotic Disorders market in Australia.In conclusion, the Psychotic Disorders market in Australia is experiencing growth and development due to customer preferences for personalized treatment options, the trend towards non-pharmacological interventions and the increasing use of digital health technologies. The local special circumstances, including the accessibility of healthcare services and government support, further contribute to the market's growth. Additionally, underlying macroeconomic factors such as a stable economy and a favorable regulatory environment support the expansion of the market in Australia.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.